Compare Wockhardt with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs LUPIN - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LUPIN WOCKHARDT/
LUPIN
 
P/E (TTM) x -26.9 -70.8 - View Chart
P/BV x 1.2 2.1 56.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT   LUPIN
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
LUPIN
Mar-19
WOCKHARDT/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,012986 102.6%   
Low Rs532720 73.8%   
Sales per share (Unadj.) Rs355.9369.5 96.3%  
Earnings per share (Unadj.) Rs-60.313.4 -449.7%  
Cash flow per share (Unadj.) Rs-46.837.4 -125.1%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.8303.7 84.9%  
Shares outstanding (eoy) m110.63452.49 24.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.3 93.9%   
Avg P/E ratio x-12.863.6 -20.1%  
P/CF ratio (eoy) x-16.522.8 -72.3%  
Price / Book Value ratio x3.02.8 106.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,379386,064 22.1%   
No. of employees `0006.317.7 35.4%   
Total wages/salary Rs m9,37131,513 29.7%   
Avg. sales/employee Rs Th6,295.09,453.8 66.6%   
Avg. wages/employee Rs Th1,498.31,782.0 84.1%   
Avg. net profit/employee Rs Th-1,066.3343.0 -310.9%   
INCOME DATA
Net Sales Rs m39,369167,182 23.5%  
Other income Rs m1,2023,640 33.0%   
Total revenues Rs m40,571170,822 23.8%   
Gross profit Rs m1828,822 0.1%  
Depreciation Rs m1,49510,850 13.8%   
Interest Rs m2,5553,078 83.0%   
Profit before tax Rs m-2,83018,534 -15.3%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-3,582-3,400 105.4%   
Tax Rs m2579,017 2.9%   
Profit after tax Rs m-6,6696,066 -109.9%  
Gross profit margin %017.2 0.3%  
Effective tax rate %-9.148.7 -18.7%   
Net profit margin %-16.93.6 -466.9%  
BALANCE SHEET DATA
Current assets Rs m33,796138,536 24.4%   
Current liabilities Rs m26,91761,299 43.9%   
Net working cap to sales %17.546.2 37.8%  
Current ratio x1.32.3 55.6%  
Inventory Days Days7984 94.7%  
Debtors Days Days89112 79.4%  
Net fixed assets Rs m39,664127,516 31.1%   
Share capital Rs m553905 61.1%   
"Free" reserves Rs m27,968136,517 20.5%   
Net worth Rs m28,522137,422 20.8%   
Long term debt Rs m21,73166,417 32.7%   
Total assets Rs m81,620279,494 29.2%  
Interest coverage x-0.17.0 -1.5%   
Debt to equity ratio x0.80.5 157.6%  
Sales to assets ratio x0.50.6 80.6%   
Return on assets %-5.03.3 -154.1%  
Return on equity %-23.44.4 -529.7%  
Return on capital %-7.78.9 -86.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80759,414 16.5%   
Fx outflow Rs m1,78922,282 8.0%   
Net fx Rs m8,01937,132 21.6%   
CASH FLOW
From Operations Rs m68416,660 4.1%  
From Investments Rs m6,302-32,825 -19.2%  
From Financial Activity Rs m-7,6957,441 -103.4%  
Net Cashflow Rs m-664-8,724 7.6%  

Share Holding

Indian Promoters % 74.5 46.6 159.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.3 11.3 20.4%  
FIIs % 7.7 31.9 24.1%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.1 152.5%  
Shareholders   67,757 98,259 69.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare WOCKHARDT With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

How to Trade this Market Crash(Podcast)

India's #1 trader, Vijay Bhambwani, decodes the crash...and reveals hidden opportunities one could profit from.

Related Views on News

GLENMARK PHARMA Plunges by 6%; BSE HEALTHCARE Index Down 3.3% (Market Updates)

Feb 28, 2020 | Updated on Feb 28, 2020

GLENMARK PHARMA share price has plunged by 6% and its current market price is Rs 292. The BSE HEALTHCARE is down by 3.3%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 3.6%) and PFIZER (up 1.6%). The top losers are GLENMARK PHARMA (down 6.1%) and DR. REDDYS LAB (down 5.1%).

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

This is What You Must Know as an Options Trader Today(Fast Profits Daily)

Feb 27, 2020

How you can stay on top of the challenges as an options trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Feb 28, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - ORCHID PHARMA LTD COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS